Macular edema secondary to uveitis. Other specified retinal disorders
Conditions
Interventions
intra vitreal injection of bevacizomab(avastin).
Treatment - Surgery
intra vitreal injection of bevacizomab(avastin)
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In a prospective clinical trial consecutive 30 patients with uveitis and CME will be enroll in the study. None of the patients will have a systemic or an ocular disease other than the one causing uveitis. Patients with history of other diseases causing macular edema (such as diabetes mellitus and retinal vein occlusions) will be excluded from the study. All of the patients should have decreased vision due to Cystoid Macular Edema (CME),
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central macular thickness. Timepoint: Before injection and 1, 3, 6 and 12 months after injection. Method of measurement: SD-OCT.;Best corrected visual acuity. Timepoint: Before injection and 1, 3, 6 and 12 months after injection. Method of measurement: Standard snelen chart and log mar. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complication of intravitreal injection of bevacizumab. Timepoint: During 1 year after injection. Method of measurement: Routine physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hooman Razmi
Shiraz University of Medical Sciences
Outcome results
None listed